In a regulatory filing, CymaBay Therapeutics disclosed that on December 19, the company and Lewis Stuart, the company’s Chief Commercial Officer, mutually agreed that Mr. Stuart will cease to be an officer and employee of CymaBay effective December 29. “Mr. Stuart will be entitled to severance in accordance with his Offer Letter dated March 24, 2021. Ben Kozub, VP Liver Franchise Lead, will assume leadership of the commercial organization effective immediately. Mr. Kozub joined CymaBay in November 2020 and has been integral in the company’s pre-commercial planning to date,” the filing stated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay price target raised to $29 from $22 at B. Riley
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CymaBay price target raised to $26 from $24 at BTIG
- CymaBay price target raised by $4 at H.C. Wainwright, here’s why
- CymaBay price target raised to $28 from $24 at H.C. Wainwright